Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 6

Tadalafil in the treatment of erectile dysfunction

Authors Robert M Coward, Culley C Carson

Published 5 December 2008 Volume 2008:4(6) Pages 1315—1329

DOI https://doi.org/10.2147/TCRM.S3336

Review by Single-blind

Peer reviewer comments 7

Robert M Coward, Culley C Carson

Division of Urologic Surgery, University of North Carolina, Chapel Hill, NC, USA

Abstract: The treatment for erectile dysfunction (ED) was revolutionized with the development of phosphodiesterase type 5 (PDE5) inhibitors. Tadalafil (Cialis®; Eli Lilly and Company, Indianapolis, IN, USA) is the newest and most versatile PDE5 inhibitor in the clinical armamentarium for the treatment of ED. Its most unique characteristic is its long half-life of 17.5 hours, which lends itself to a longer therapeutic window with on-demand dosing and effective steady-state plasma concentrations with once-daily dosing. Clinical trials have proven its safety and efficacy with both dosing strategies for all severities and etiologies of ED, including difficult-to-treat ED. This thorough review will discuss ED, the physiology of penile erection and the role of PDE5, and all aspects of tadalafil, from its development, through its pharmacology, to its latest clinical studies and indications.

Keywords: tadalafil, Cialis, PDE5 inhibitors, phosphodiesterase type 5, erectile dysfunction, penile erection

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Unusual case of contralateral Horner's syndrome following stellate-ganglion block: a case report and review of the literature

Amhaz HH, Manders L, Chidiac EJ, Pallekonda V, Chakrabortty S

Local and Regional Anesthesia 2013, 6:31-33

Published Date: 10 October 2013

Safety and efficacy of MIM D3 ophthalmic solutions in a randomized placebo controlled Phase 2 clinical trial in patients with dry eye

Meerovitch K, Torkildsen G, Lonsdale J, Goldfarb H, Lama T, Cumberlidge G, Ousler GW III

Clinical Ophthalmology 2013, 7:1275-1285

Published Date: 26 June 2013

Histopathologic correlation of Aspergillus endophthalmitis following uncomplicated cataract surgery

Haddock LJ, Flynn HW Jr, Dubovy SR, Khurana RN, Egbert PR

Clinical Ophthalmology 2012, 6:1573-1577

Published Date: 25 September 2012

Descemet-stripping automated endothelial keratoplasty for vitrectomized cases with traumatic aniridia and aphakic bullous keratopathy

Eguchi H, Miyamoto T, Hotta F, Tomida M, Inoue M, Mitamura Y

Clinical Ophthalmology 2012, 6:1513-1518

Published Date: 17 September 2012

Effects of protein and omega-3 supplementation, provided during regular dialysis sessions, on nutritional and inflammatory indices in hemodialysis patients

Mat Daud ZA, Tubie B, Adams J, Quainton T, Osia R, Tubie S, Kaur D, Khosla P, Sheyman M

Vascular Health and Risk Management 2012, 8:187-195

Published Date: 20 March 2012

Update on the treatment of disseminated fusariosis: Focus on voriconazole

Marta Stanzani, Fabio Tumietto, Nicola Vianelli, Michele Baccarani

Therapeutics and Clinical Risk Management 2007, 3:1165-1173

Published Date: 15 January 2008

Optimal timing for antihypertensive dosing: focus on valsartan

Ramón C Hermida, Diana E Ayala, Carlos Calvo

Therapeutics and Clinical Risk Management 2007, 3:119-131

Published Date: 15 March 2007